EUS could detect ascites missed by CT scan [4] by Lee, YT et al.
Title EUS could detect ascites missed by CT scan [4]
Author(s) Chu, KM; Lee, YT; Ng, EK
Citation Gut, 2006, v. 55 n. 10, p. 1524
Issued Date 2006
URL http://hdl.handle.net/10722/45371
Rights Gut. Copyright © B M J Publishing Group.
EUS could detect ascites missed
by CT scan
I read with great interest the article by Lee
and colleagues (Gut 2005;54:1541–5) regard-
ing the accuracy of endoscopic ultrasonogra-
phy (EUS) in diagnosing ascites and
predicting peritoneal metastases in patients
with gastric cancer. I would like to thank the
authors for quoting our study.1 Lee and
colleagues commented that the sensitivity of
detection of ascites was lower in our study
and that this might be due to the use of
catheter probe. I would however like to point
out that such a comparison was unfair as the
two studies were fundamentally different in
two ways.
(1) The patient populations of the two
studies were different. Our study excluded all
patients with evidence of ascites on physical
examination or computed tomography (CT)
scan. We believe that there is no need for an
additional EUS to confirm the presence of
ascites in such patients. Moreover, such
patients should have paracentesis for cytol-
ogical examination rather than a locoregional
staging investigation like EUS.
During the study period of our paper
(September 1995 to January 2002), 89
patients had evidence of ascites on CT scan
or physical examination. There would be no
difficulty in detecting ascites in these patients
by EUS. If we included these patients, the
detection rate by EUS would have been 25.5%
(36+89/402+89 = 125/491). The overall inci-
dence of ascites was 29.5% (56+89/
402+89 = 145/491). The ‘‘adjusted’’ sensitiv-
ity would be 84.8% (34+89/56+89 = 123/145),
not much lower than the 87.1% reported by
Lee et al.
(2) CT scan was performed for all patients
in our study. Of the 89 patients who were
excluded from the study, 69 had evidence of
ascites on CT scan. The sensitivity of CT scan
for detection of ascites was 47.6% (69/145),
higher than the 16.1% sensitivity (combined
US and CT scan) reported by Lee et al. We
suspect the lower sensitivity may be due to
the predominant use of US scan (231
patients) rather than CT scan (99 patients)
in their study. A direct comparison however
is not possible as the study populations of the
two studies may be different.
In summary, I would like to applaud Lee et
al for their systematic study. The comment
that the sensitivity of detection of ascites was
lower in our study was unfair.
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Author’s reply
We would like to thank Dr Chu for his
interest in our paper and for supplementing
some of the data missing in his previous
publication.1 We agree that both studies had
fundamental difference in study design and
we would like to point out the major
difference for discussion.
One of the major differences lies in the
definition of presence of ascites. Chu et al
used positive laparoscopic detection of ascites
as the gold standard when comparing with
their endoscopic ultrasonography (EUS)
findings. However, in our study, we com-
bined all investigation results (ultrasound
(US), computed tomography (CT), EUS, and
operation) to determine the status of ascites.
We believe that a small amount of fluid, such
as several millilitres as detected by EUS,
might not be visibly appreciated during
operation.
Another major difference is the type of EUS
used in the two studies. We used an
echoendoscope (7.5–12 MHz) with a higher
penetration depth, which allowed scanning
through thick tumours. In contrast, Chu et al
used a miniprobe (20 MHz) in their study,
which actually had a limited depth of
penetration. This may explain why the overall
incidence of ascites was higher in our study
(37.2%) compared with Chu’s series (29.5%,
the supplemented data combining CT, physi-
cal examination, and operative finding). In
our study, EUS was more sensitive (87.1%)
than the operative findings (40.9%) in
detecting ascites. Therefore, we do not agree
with Chu’s conclusion that ‘‘laparoscopy and
laparotomy remain the reference standard for
the detection of ascites’’ as ‘‘ascites was
missed by EUS in nearly 40% of patients’’.1
We suspect if an echoendoscope was used in
Chu’s study, the sensitivity of EUS would
have increased and CT decreased, and the
projected results would then have come close
to ours.
In fact, CT scan is not our routine in the
preoperative assessment of patients with
gastric cancer, especially in those early gastric
cancers, or if EUS showed no local invasion.
There is no evidence in the literature showing
that CT scan is better than US in the
detection of ascites. CT scan could not be
used as the gold standard as, according to
Chu’s data, CT scan missed 20 patients with
ascites which was indeed detectable on
physical examination.
We are however agreed on the same
conclusion that ‘‘EUS is useful for the
detection of ascites in patients with gastric
carcinoma’’ and ‘‘The presence of ascites was
significantly associated with peritoneal seed-
ing’’.1
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Anti-TNF-a therapy for orofacial
granulomatosis: proceed with
caution
A 36 year old female patient was reviewed at
the gastrointestinal clinic. She had, since the
age of 15 years, been affected by troublesome
orofacial granulomatosis (OFG) manifest as
lower lip swelling together with a midline
fissure. In the past she had received numer-
ous therapies, including intralesional and
systemic corticosteroid (short term benefit
only), cinnamon and a benzoate free diet
(lack of compliance), azathioprine (intoler-
ance), and topical tacrolimus (ineffective).
In 2001, due to increasing distress about
her appearance compounded by her forth-
coming wedding, we decided to treat her with
an infliximab infusion at 5 mg/kg. Within
seven days there was a noticeable improve-
ment, followed by complete healing of her
labial fissure six weeks later, just prior to her
wedding. Two weeks after this she found out
she was pregnant. She subsequently gave
birth to a healthy baby boy but failed to
attend the clinic and was lost to follow up for
four years.
On re-referral to the clinic in 2005, she was
in the midst of a course of oral prednisolone
(prescribed by her general practitioner) as her
OFG had once again become problematic. In
view of her excellent previous response to
anti-tumour necrosis factor a (TNF-a) ther-
apy coupled with the significant risks of an
infusion reaction if rechallenged with inflix-
imab (long drug ‘‘holiday’’ with no concomi-
tant immunosuppression), we elected to treat
her with subcutaneous adalimumab, 80 mg
initially and then 40 mg fortnightly. After
five weeks of treatment there was both a
subjective and objective improvement, with
partial healing of the midline fissure (figs 1,
2). At eight weeks the patient noted some left
sided facial pain and swelling just below the
corner of her mouth. She attended her dentist
who excluded any peridontal sepsis. Three
days later she was admitted to our unit with
fever sweats and worsening facial pain and
swelling (fig 3). Clinically she had a perioral
cellulitis with bilateral perioral swelling
and erythema, together with pyrexia and
raised inflammatory indices. She received
Figure 1 Pre-adalimumab treatment; swollen
lower lip with deep midline fissure.
Figure 2 At five weeks, after three
adalimumab injections; marked improvement in
midline fissure.
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